Workout
Healthy Eating
Meditation
Podcast
Authenticity
Social Service
About Us
Review Board
Editorial Process
Contact Us
Health Tracker
AI Tools
✔Fact Checked

The European giant makes an offer to Dani Olmo in the midst of Barcelona’s nightmare

Dani Olmo’s agent, Andy Barça, has stated twice in the last week that his client’s desire is to stay at Barcelona, ​​and once that he does not listen to offers from other teams. However, that won’t stop them from arriving.

Chelsea, Arsenal, Manchester City and Paris Saint-Germain are just some of the teams reportedly monitoring Olmo’s situation, with a view to taking advantage of a notable opportunity to sign him on a free transfer. However, the first team to make their move is AC Milan.

According to CdS, and quoted by Sport, the Rossoneri have offered Olmo a short-term deal. They are willing to match his salary at Barcelona with a six-month contract, which will allow him to return to the Blaugrana in the summer. They would provide him with a starting spot at a major club and in the Champions League for the remainder of the season.

At the moment it seems that Olmo will wait to see how the legal case brought by Barcelona develops. The Blaugrana hope to obtain a precautionary measure to keep Olmo registered with the Ministry of Sports, and if not, in the ordinary justice system. However, Barça and Olmo will surely consider their options in the event of a negative result.

Last reviewed on

Expert Q&A

Ask a Question
Share Now:

Was this article helpful?

🤓

😕

dotdash removebg preview

FitToFar is part of the Dotdash Meredith publishing family.

Please review our updated Terms of Service.

BE THE FIRST TO KNOW

SUBSCRIBE TO GET LATEST FITNESS AND NUTRITION UPDATES!

We don’t spam! Read our privacy policy for more info.

The FitToFar News team takes pride in providing readers with accurate, properly sourced, and objectively analyzed content. Each news piece is stringently fact-checked by our Integrity Network, and any form of plagiarism or malicious behavior from our authors and contributors is strictly forbidden.

Our articles follow a number of key standards:

  • Each cited research and studies should come from renowned peer-reviewed journals or educational bodies. Additionally, any quoted data and figures must be traceable to its origin, while also detailing their significance.

  • Content related to treatment, medicine, and procedure must plainly specify availability, cost, possible side effects, targets, possible interactions, and unapproved usage (if relevant).

  • Every news article should have inputs from at least two authorized professionals, with corresponding qualifications and ties to appropriate associations or works.

  • The reader must be made aware of any potential conflict of interest relating to the source or study.

  • Finally, all news pieces should be supplied with enough background and context regarding the relevant topic or condition.